Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance

BACKGROUND: Patients with BRAF mutation-positive advanced melanoma respond well to matched therapy with BRAF or MEK inhibitors, but often quickly develop resistance. METHODS: Tumor tissue from ten patients with advanced BRAF mutation-positive melanoma who achieved partial response (PR) or complete r...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:BMC Cancer
Egile Nagusiak: Wheler, Jennifer, Yelensky, Roman, Falchook, Gerald, Kim, Kevin B, Hwu, Patrick, Tsimberidou, Apostolia M, Stephens, Philip J, Hong, David, Cronin, Maureen T, Kurzrock, Razelle
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2015
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4340232/
https://ncbi.nlm.nih.gov/pubmed/25886620
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1029-z
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak